Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?

被引：112

作者：

de Charette, Marie ^{[1
]}

Marabelle, Aurelien ^{[2
,3
]}

Houot, Roch ^{[1
,4
]}

机构：

[1] CHU Rennes, Serv Hematol Clin, F-35033 Rennes, France

[2] Univ Paris Saclay, Gustave Roussy, Dept Innovat Therapeut & Essais Precoces, F-94805 Villejuif, France

[3] INSERM, U1015, F-94805 Villejuif, France

[4] INSERM, U917, F-35043 Rennes, France

来源：

EUROPEAN JOURNAL OF CANCER | 2016年 / 68卷

关键词：

Cancer; Immunotherapy; Checkpoint inhibitors; Antigen presentation; MHC CLASS-I; CHRONIC LYMPHOCYTIC-LEUKEMIA; HISTONE DEACETYLASE INHIBITORS; ACUTE MYELOID-LEUKEMIA; HLA-DR EXPRESSION; MATURE DENDRITIC CELLS; POOR PATIENT SURVIVAL; B-LYMPHOMA-CELLS; COSTIMULATORY MOLECULES; MELANOMA-CELLS;

D O I：

10.1016/j.ejca.2016.09.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Downregulation/loss of the antigen presentation is a major immune escape mechanism in cancer. It allows tumour cells to become 'invisible' and avoid immune attack by antitumour T cells. In tumour harbouring properties of professional antigen presenting cells (i.e. tumour B cells in lymphoma), downregulation/loss of the antigen presentation may also prevent direct priming of naive T cells by tumour cells. Here, we review treatments that may induce/restore antigen presentation by the tumour cells. These treatments may increase the generation of antitumour T cells and/or their capacity to recognise and eliminate tumour cells. By forcing tumour cells to present their antigens, these treatments may sensitise patients to T cellebased immunotherapies, including checkpoint inhibitors. (C) 2016 Elsevier Ltd. All rights reserved.

引用

页码：134 / 147

页数：14

共 137 条

[1] CD40 Ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I- and class II-binding peptides [J].

Ahmadi, Tahamtan ;

Flies, Amanda ;

Efebera, Yvonne ;

Sherr, David H. .

IMMUNOLOGY, 2008, 124 (01) :129-140

[2] Role for CD40-CD40 ligand interactions in the immune response to solid tumours [J].

Alexandroff, AB ;

Jackson, AM ;

Paterson, T ;

Haley, JL ;

Ross, JA ;

Longo, DL ;

Murphy, WJ ;

James, K ;

Taub, DD .

MOLECULAR IMMUNOLOGY, 2000, 37 (09) :515-526

[3] Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia [J].

Andritsos, Leslie A. ;

Johnson, Amy J. ;

Lozanski, Gerard ;

Blum, William ;

Kefauver, Cheryl ;

Awan, Farrukh ;

Smith, Lisa L. ;

Lapalombella, Rosa ;

May, Sarah E. ;

Raymond, Chelsey A. ;

Wang, Da-Sheng ;

Knight, Robert D. ;

Ruppert, Amy S. ;

Lehman, Amy ;

Jarjoura, David ;

Chen, Ching-Shih ;

Byrd, John C. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15) :2519-2525

[4] MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment In Vitro [J].

Angell, Trevor E. ;

Lechner, Melissa G. ;

Jang, Julie K. ;

LoPresti, Jonathan S. ;

Epstein, Alan L. .

CLINICAL CANCER RESEARCH, 2014, 20 (23) :6034-6044

[5] Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity [J].

Armstrong, TD ;

Clements, VK ;

Martin, BK ;

Ting, JPY ;

OstrandRosenberg, S .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (13) :6886-6891

[6] Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia [J].

Atanackovic, Djordje ;

Luetkens, Tim ;

Kloth, Benjamin ;

Fuchs, Gregor ;

Cao, Yanran ;

Hildebrandt, York ;

Meyer, Sabrina ;

Bartels, Katrin ;

Reinhard, Henrike ;

Lajmi, Nesrine ;

Hegewisch-Becker, Susanna ;

Schilling, Georgia ;

Platzbecker, Uwe ;

Kobbe, Guido ;

Schroeder, Thomas ;

Bokemeyer, Carsten ;

Kroeger, Nicolaus .

AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (11) :918-922

[7] Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia [J].

Aue, Georg ;

Njuguna, Ndegwa ;

Tian, Xin ;

Soto, Susan ;

Hughes, Thomas ;

Vire, Berengere ;

Keyvanfar, Keyvan ;

Gibellini, Federica ;

Valdez, Janet ;

Boss, Carol ;

Samsel, Leigh ;

McCoy, J. Philip, Jr. ;

Wilson, Wyndham H. ;

Pittaluga, Stefania ;

Wiestner, Adrian .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (09) :1266-1273

[8] Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma [J].

Azimi, Farhad ;

Scolyer, Richard A. ;

Rumcheva, Pavlina ;

Moncrieff, Marc ;

Murali, Rajmohan ;

McCarthy, Stanley W. ;

Saw, Robyn P. ;

Thompson, John F. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) :2678-2683

[9] Methylation of CIITA promoter IV causes loss of HLA-II inducibility by IFN-γ in promyelocytic cells [J].

Barbaro, Andrea De Lerma ;

De Ambrosis, Alessandro ;

Banelli, Barbara ;

Pira, Giuseppina Li ;

Aresu, Ottavia ;

Romani, Massimo ;

Ferrini, Silvano ;

Accolla, Roberto S. .

INTERNATIONAL IMMUNOLOGY, 2008, 20 (11) :1457-1466

[10] Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials [J].

Bernd, Heinz-Wolfram ;

Ziepert, Marita ;

Thorns, Christoph ;

Klapper, Wolfram ;

Wacker, Hans-Heinrich ;

Hummel, Michael ;

Stein, Harald ;

Hansmann, Martin-Leo ;

Ott, German ;

Rosenwald, Andreas ;

Mueller-Hermelink, Hans-Konrad ;

Barth, Thomas F. E. ;

Moeller, Peter ;

Cogliatti, Sergio B. ;

Pfreundschuh, Michael ;

Schmitz, Norbert ;

Truemper, Lorenz ;

Hoeller, Silvia ;

Loeffler, Markus ;

Feller, Alfred C. .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (11) :1569-1580

← 1 2 3 4 5 6 7 8 9 10 →